{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T16:29:43Z","timestamp":1785860983028,"version":"3.56.0"},"reference-count":15,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2006,6]]},"DOI":"10.1097\/01.ftd.0000196662.35726.0f","type":"journal-article","created":{"date-parts":[[2006,6,14]],"date-time":"2006-06-14T04:36:49Z","timestamp":1150259809000},"page":"375-381","source":"Crossref","is-referenced-by-count":24,"title":["Development and Clinical Evaluation of Two Chromogenic Substrate Methods for Monitoring Fondaparinux Sodium"],"prefix":"10.1097","volume":"28","author":[{"given":"C.","family":"Klaeffling","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Piechottka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Daemgen-von Brevern","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Mosch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Mani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Luxembourg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Lindhoff-Last","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-17-20210129","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1056\/NEJMoa011099","article-title":"Fondaparinux compared with enoxaparin for prevention of venous thromboembolism after elective major knee surgery","volume":"345","author":"Bauer","year":"2001","journal-title":"N Engl J Med"},{"key":"R2-17-20210129","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1056\/NEJMoa011100","article-title":"Fondaparinux compared with enoxaparin for prevention of venous thromboembolism after hip-fracture surgery","volume":"345","author":"Eriksson","year":"2001","journal-title":"N Engl J Med"},{"key":"R3-17-20210129","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1016\/S0140-6736(02)08652-X","article-title":"Postoperative Fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip-replacement surgery: a randomised double blind trial","volume":"359","author":"Lassen","year":"2002","journal-title":"Lancet"},{"key":"R4-17-20210129","doi-asserted-by":"crossref","first-page":"867","DOI":"10.7326\/0003-4819-140-11-200406010-00007","article-title":"Matisse Investigators. Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial","volume":"140","author":"Buller","year":"2004","journal-title":"Ann Intern Med"},{"key":"R5-17-20210129","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1056\/NEJMoa035451","article-title":"Matisse Investigators. Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism","volume":"349","author":"Buller","year":"2003","journal-title":"N Engl J Med"},{"key":"R6-17-20210129","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1055\/s-0038-1649967","article-title":"Pharmacokinetics and tolerance of the natural pentasaccharide (SR 90107\/ORG-31540) with high affinity to antithrombin III in man","volume":"74","author":"Boneu","year":"1995","journal-title":"Thromb Haemost"},{"key":"R7-17-20210129","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1055\/s-0038-1649968","article-title":"The effect of the synthetic pentasaccharide SR 90107\/ORG 31540 on thrombin generation ex vivo is uniquely due to AT mediated neutralization of Factor Xa","volume":"74","author":"Lormeau","year":"1995","journal-title":"Thromb Haemost"},{"key":"R8-17-20210129","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1055\/s-2002-34309","article-title":"The synthetic pentasaccharide fondaparinux: first in the class of antithrombotic agents that selectively inhibit coagulation factor Xa","volume":"28","author":"Petitou","year":"2002","journal-title":"Semin Thromb Hemost"},{"key":"R9-17-20210129","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1527-3466.1997.tb00321.x","article-title":"SR 90107 A\/Org 31540, a novel anti-factor Xa antithrombotic agent","volume":"15","author":"Herbert","year":"1997","journal-title":"Cardiovasc Drug Rev"},{"issue":"2","key":"R10-17-20210129","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00003088-200241002-00001","article-title":"The pharmacokinetics of fondaparinux sodium in healthy volunteers","volume":"41","author":"Donat","year":"2002","journal-title":"Clin Pharmacokinet"},{"key":"R11-17-20210129","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1055\/s-0037-1613092","article-title":"Absence of placental transfer of pentasaccharide (Fondaparinux, Arixtra\u00ae) in the dually perfused cotyledon in vitro","volume":"87","author":"Lagrange","year":"2002","journal-title":"Thromb Haemost"},{"key":"R12-17-20210129","first-page":"451","article-title":"Two sensitive and rapid chromogenic assays of Fondaparinux Sodium (Arixtra\u00ae) in human plasma and other biological matrices","volume":"49","author":"Paolucci","year":"2003","journal-title":"Clin Lab"},{"key":"R13-17-20210129","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1111\/j.1538-7933.2004.0584a.x","article-title":"Assessment of three chromogenic and one clotting assays for the measurement of synthetic pentasaccharide fondaparinux (Arixtra\u00ae) anti-Xa activity","volume":"2","author":"Depasse","year":"2003","journal-title":"J Thromb Haemost"},{"issue":"Suppl","key":"R14-17-20210129","doi-asserted-by":"crossref","first-page":"188S","DOI":"10.1378\/chest.126.3_suppl.188S","article-title":"Heparin and low-molecular weight heparin: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy","volume":"126","author":"Hirsh","year":"2004","journal-title":"Chest"},{"key":"R15-17-20210129","doi-asserted-by":"crossref","first-page":"2726","DOI":"10.1161\/01.CIR.102.22.2726","article-title":"Treatment of proximal deep vein thrombosis with a novel synthetic compound (SR90107A\/ORG31540) with pure anti-factor Xa activity","volume":"102","year":"2000","journal-title":"Circulation"}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/01.ftd.0000196662.35726.0f","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T15:36:35Z","timestamp":1785857795000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00007691-200606000-00017"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,6]]},"references-count":15,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2006]]}},"URL":"https:\/\/doi.org\/10.1097\/01.ftd.0000196662.35726.0f","relation":{},"ISSN":["0163-4356"],"issn-type":[{"value":"0163-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2006,6]]}}}